Hypertension on the NP Exam: Staging, When to Start Medication and the First Drug

Hypertension questions on the FNP and AGNP exams turn on three decisions, and the 2025 AHA/ACC guideline governs all of them. First, stage the pressure from the average of properly measured readings on two or more visits, confirmed with home or ambulatory monitoring. Second, decide whether medication starts now or after a lifestyle trial: stage 2 starts now, and stage 1 starts now only with cardiovascular disease, diabetes, chronic kidney disease or a 10-year PREVENT risk of 7.5 percent or higher. Third, choose the first drug from the three first-line classes, and start two of them together in stage 2. The treatment goal for most adults is under 130/80.

Screening and measurement

The USPSTF (2021, grade A) recommends screening adults 18 and older with office measurement: yearly from age 40 and for adults at increased risk (Black adults, high-normal readings, overweight or obesity), and every 3 to 5 years for adults 18 to 39 at low risk with a prior normal reading. Out-of-office confirmation comes before treatment.

Technique appears in vignettes. The standard is a validated upper-arm cuff of the right size, the patient seated with back supported, feet flat and arm at heart level, after 5 minutes of rest, with no caffeine, exercise or smoking in the preceding 30 minutes and an empty bladder. Two readings a minute apart are averaged. Cuffless devices such as smartwatches are not used for diagnosis or management.

Out-of-office monitoring confirms the diagnosis and separates two phenotypes the exam likes:

• White coat hypertension: high office readings, normal home or ambulatory readings. Lifestyle advice and periodic reassessment, no medication for the office number alone.
• Masked hypertension: normal office readings, elevated home readings. Risk tracks the home readings, so the patient is managed as hypertensive.

Staging: the 2017 categories still stand

When systolic and diastolic fall into different categories, the higher category is assigned.

The 2025 guideline uses "severe hypertension" in place of "hypertensive urgency" and warns that aggressive intravenous or as-needed lowering of an asymptomatic high number causes harm. Acute target-organ damage means encephalopathy, stroke or intracranial hemorrhage, acute coronary syndrome, acute heart failure, aortic dissection, acute kidney injury or eclampsia.

The initial evaluation

The basic work-up carried forward from 2017 includes fasting glucose, complete blood count, lipid profile, serum creatinine with eGFR, sodium, potassium and calcium, TSH, urinalysis and a 12-lead ECG. The 2025 guideline adds a urine albumin-to-creatinine ratio for every adult with hypertension, because albuminuria changes both the risk estimate and the drug choice.

Secondary causes are screened on clinical clues: onset before age 30, abrupt onset or worsening, resistant hypertension, hypokalemia, an adrenal incidentaloma, sleep apnea symptoms, or drug and alcohol use. Screening for primary aldosteronism with an aldosterone-to-renin ratio is a class 1 recommendation in every adult with resistant hypertension, whatever the potassium, and most antihypertensives can continue during testing except mineralocorticoid receptor antagonists.

Risk estimation: PREVENT replaces the Pooled Cohort Equations

The AHA PREVENT equations (Khan et al., 2023) estimate 10-year and 30-year risk of total cardiovascular disease, including heart failure, in adults 30 to 79 without known cardiovascular disease. Inputs are age, sex, total and HDL cholesterol, systolic pressure, diabetes, smoking, body mass index, eGFR and treatment status, with optional albuminuria, A1c and a social deprivation index. Race is not an input.

The threshold for medicating stage 1 is now a 10-year PREVENT risk of 7.5 percent or higher; the 2017 threshold was a 10-year ASCVD risk of 10 percent. Read which calculator a vignette names. Diabetes and CKD remain stand-alone triggers whatever the calculated risk.

Deciding when medication starts

The goal of under 130/80 applies to most adults, including community-dwelling adults 65 and older, and a systolic pressure under 120 is encouraged when it is reached without adverse effects. Frailty, limited life expectancy, institutional care and orthostatic hypotension call for shared decision-making. A systolic goal under 130 is also a class 1 recommendation to lower the risk of mild cognitive impairment and dementia.

Lifestyle change: the exam wants specifics

Lifestyle change is the whole plan for elevated pressure and low-risk stage 1 for 3 to 6 months, and the foundation at every other stage:

• Weight loss, with at least 5 percent as the first goal in adults with overweight or obesity.
• A DASH-pattern diet.
• Sodium under 2,300 mg per day, ideally under 1,500 mg.
• More dietary potassium; potassium-enriched salt substitutes are a class 2a option for adults without CKD and not on potassium-retaining drugs.
• Aerobic activity most days plus resistance training.
• Alcohol: none or as little as possible, and no more than 2 drinks per day for men or 1 for women.

A GLP-1 receptor agonist can be considered for adults with hypertension and overweight or obesity.

Choosing the first drug

The first-line classes are unchanged from 2017: a thiazide-type diuretic, a long-acting dihydropyridine calcium channel blocker, or an ACE inhibitor or ARB. Any one is acceptable as monotherapy in stage 1 without a compelling indication. Beta blockers are not first-line for uncomplicated hypertension. An ACE inhibitor and an ARB are never combined.

The 2017 guideline recommended a thiazide-type diuretic or calcium channel blocker as the first drug for Black adults without heart failure or CKD; confirm in the current guideline how the 2025 text handles this. Items are more likely to test comorbidity than race.

One drug or two

A single agent lowers systolic pressure by roughly 10 mm Hg. Starting two first-line agents from different classes, preferably as a single-pill combination, is a class 1 recommendation in stage 2 hypertension. A patient at 152/94 with a goal of under 130/80 qualifies. Standard pairings are an ACE inhibitor or ARB with a thiazide-type diuretic, or with amlodipine. Once-daily dosing and single pills improve adherence.

Follow-up and titration

Reassess about 1 month after starting or changing medication, reviewing adherence, home readings and adverse effects, and repeat monthly until the goal is met, then every 3 to 6 months. If a moderate dose of one drug falls short, adding a second class works better than pushing the first to its maximum, because adverse effects climb faster than benefit at the top of most dose ranges. Home readings guide titration, and team-based care with nurses and pharmacists helps uncontrolled patients. Adults on lifestyle change alone are reassessed in 3 to 6 months.

Resistant hypertension and referral

Resistant hypertension is pressure above goal on three drugs of different classes, including a diuretic, at maximally tolerated doses, or control that requires four or more. First exclude pseudo-resistance: poor technique, nonadherence, white coat effect, and interfering substances such as NSAIDs, decongestants, oral contraceptives, stimulants, alcohol and licorice. True resistance prompts screening for primary aldosteronism and sleep apnea, a switch to a long-acting thiazide-type diuretic, and spironolactone as the usual fourth drug. Renal denervation may be considered (class 2b) at experienced centers.

Refer for resistant hypertension, a positive secondary-cause screen, eGFR under 30 or falling quickly, unexplained hypertension before age 30, or hypertension in pregnancy without obstetric co-management.

Patient education

Teach home monitoring with a validated upper-arm cuff: two readings morning and evening for 7 days before a visit, with the log brought in. Explain that treatment is long-term, that some agents should not be stopped abruptly, and that lightheadedness on standing needs reporting, especially in older adults. Women of reproductive age started on an ACE inhibitor or ARB need contraception counseling and a plan to switch before conception.

How the exam tests this

• The single-reading trap. One office reading of 142/90 with no confirmation calls for out-of-office monitoring or a repeat visit, not a prescription. Only an emergency bypasses confirmation.
• The old-threshold trap. Stage 1 with a PREVENT risk of 8 percent gets medication now; 6 percent gets 3 to 6 months of lifestyle change. Older items use a 10 percent ASCVD cutoff.
• The one-drug trap. Stage 2 at 156/96 in a healthy adult calls for two first-line agents, not amlodipine alone.
• The beta blocker trap. A beta blocker is the first drug only with HFrEF, prior infarction or angina in the stem.
• The pregnancy trap. ACE inhibitors, ARBs and direct renin inhibitors are wrong in pregnancy or planned pregnancy; labetalol and extended-release nifedipine are preferred.
• The urgency trap. A pressure of 186/118 with a mild headache and no neurologic, chest or kidney findings is severe hypertension: oral therapy and follow-up within days.
• The lab trap. After an ACE inhibitor or ARB, check potassium and creatinine in 1 to 2 weeks; a modest creatinine rise is expected (confirm the tolerated rise in the current guideline).

Practice question

A 56-year-old woman presents for follow-up of elevated readings found at a dental visit. She has no diabetes, kidney disease or cardiovascular disease, takes no medications and does not smoke. Averaged seated readings with a validated cuff are 154/96 mm Hg today and 150/94 mm Hg two weeks ago; a 7-day home log averages 148/92 mm Hg. Body mass index is 31. Fasting glucose is 98 mg/dL, eGFR is 88 mL/min/1.73 m2, potassium is 4.1 mEq/L and urine albumin-to-creatinine ratio is 12 mg/g. Her 10-year PREVENT risk is 9 percent. Which of the following is the most appropriate initial management?

• A. Lifestyle modification with home monitoring and reassessment in 3 months
• B. Lisinopril 10 mg daily with reassessment in 1 month
• C. A single-pill combination of an ARB and a thiazide-type diuretic with reassessment in 1 month
• D. Metoprolol succinate 50 mg daily with reassessment in 1 month

Answer: C. Her confirmed average is stage 2 and sits more than 20/10 mm Hg above the goal of under 130/80, so the guideline calls for two first-line agents from different classes, preferably in one pill, with lifestyle change and follow-up in about a month. Option A is the plan for stage 1 with a PREVENT risk under 7.5 percent and is wrong for stage 2 regardless of risk. Option B is a correct first-line class, but a single agent is unlikely to close a gap of 24/16 mm Hg and the guideline specifies two agents in stage 2. Option D is a beta blocker, which is not first-line without a compelling indication such as heart failure or prior infarction.

Key points

Related NPPace guides

• Statin Decisions by ASCVD Risk: Who Gets a Statin, Which Intensity and How to Monitor
• Atrial Fibrillation in the Clinic: CHA2DS2-VASc, Anticoagulant Choice and Rate Control
• Choosing the First Antihypertensive by Comorbidity: Diabetes, CKD, Heart Failure, Pregnancy and Age
• How to Read a Primary-Care Vignette Like a Provider: The 5-Step Method
• AANP vs ANCC: Which NP Certification Exam Should You Take?